| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases
|
Chan, Kwok Ying
|
|
|
9 |
7 |
p. e473-e474
|
artikel
|
| 2 |
Associations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCS): a prospective cohort study
|
Miles, Lachlan F
|
|
|
9 |
7 |
p. e514-e522
|
artikel
|
| 3 |
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia
|
Short, Nicholas J
|
|
|
9 |
7 |
p. e535-e545
|
artikel
|
| 4 |
Climate change and haematology: perspectives from the Philippines
|
Ong, Bradley Ashley G
|
|
|
9 |
7 |
p. e468-e469
|
artikel
|
| 5 |
Correction to Lancet Haematol 2022; 9: e200–07
|
|
|
|
9 |
7 |
p. e475
|
artikel
|
| 6 |
Counting the carbon cost of heparin: an evolving tragedy of the commons?
|
Fan, Bingwen Eugene
|
|
|
9 |
7 |
p. e469-e471
|
artikel
|
| 7 |
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
|
Ryu, Yun Kyoung
|
|
|
9 |
7 |
p. e463-e465
|
artikel
|
| 8 |
Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success
|
George, Lindsey A
|
|
|
9 |
7 |
p. e465-e466
|
artikel
|
| 9 |
First, do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation
|
Perram, Jacinta
|
|
|
9 |
7 |
p. e476-e477
|
artikel
|
| 10 |
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis
|
Campbell, Christine M
|
|
|
9 |
7 |
p. e546
|
artikel
|
| 11 |
Iron deficiency: effects beyond anaemia?
|
Choorapoikayil, Suma
|
|
|
9 |
7 |
p. e466-e468
|
artikel
|
| 12 |
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
|
Hochman, Michael J
|
|
|
9 |
7 |
p. e523-e534
|
artikel
|
| 13 |
Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance
|
Venugopal, Sangeetha
|
|
|
9 |
7 |
p. e462-e463
|
artikel
|
| 14 |
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
|
Passamonti, Francesco
|
|
|
9 |
7 |
p. e480-e492
|
artikel
|
| 15 |
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial
|
Xue, Feng
|
|
|
9 |
7 |
p. e504-e513
|
artikel
|
| 16 |
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
|
Song, Yuqin
|
|
|
9 |
7 |
p. e493-e503
|
artikel
|
| 17 |
The dystopia of enforced childbirth
|
The Lancet Haematology,
|
|
|
9 |
7 |
p. e461
|
artikel
|
| 18 |
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm
|
Bakalov, Veli
|
|
|
9 |
7 |
p. e478-e479
|
artikel
|
| 19 |
Transparently report on the process of moving from evidence to recommendation
|
Lv, Meng
|
|
|
9 |
7 |
p. e472
|
artikel
|
| 20 |
Transparently report on the process of moving from evidence to recommendation – Authors' reply
|
Stemler, Jannik
|
|
|
9 |
7 |
p. e472-e473
|
artikel
|
Tijdschrift beschrijving